Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A concise guide to spotting tax-friendly dividend ETFs, including key metrics and quick tips to boost after-tax performance.
22,830 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A fresh Miladys loyalty pledge stirs controversy in the Ethereum community, pitting branding loyalties against core p...
The Department of Justice confirmed an active antitrust inquiry into the U.S. beef industry, targeting major meatpack...
NVIDIA’s shares hover near $198 as investors weigh whether the AI leader’s growth justifies a premium. The stock now ...
AppLovin is set to report Q1 2026 after the close, with traders eyeing revenue momentum, margins and AI advertising s...
Ibotta's Q1 2026 earnings reveal a company balancing rapid user growth with a longer road to sustainable profitabilit...
Ethereum sits in a tight range while on-chain tokenized Treasuries on the network surpass $8 billion, marking a major...
Disney beats Q2 expectations, sending Wall Street into a target-upgrade cycle. JPMorgan, Barclays and Guggenheim lift...
A single wall street analyst thinks Tilray could deliver a sizable rally in the coming weeks. This article breaks dow...
Bitcoin price falls below a crucial support level as traders weigh macro signals and rising leverage. The move raises...
A clear guide to reading RMTI's Q1 2026 earnings call, what the numbers mean, and how to spot the catalysts that can ...
The Trade Desk has faced a tough stretch, but patient investors are asking if the trade desk stock finally offers a p...